Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who started this subject	2/12/2004 4:03:38 PM
From: bob zagorin	Read Replies (1) of 590

re. erbitux ann. excellent post (imo) from yahoo thread.. Re: What is the relationship? by: rawbbe (33/M/Sunnyvale, CA) 02/12/04 03:33 pm Msg: 11152 of 11153 Abgenix has a drug in its pipeline is very similar to Erbitux. Abgenix's version is called ABX-EGF. Both drugs are monoclonal antibodies that has been designed to bind exclusively to the epidermal growth factor receptor (EGFR). When bound to the receptor, it is intended to block the ability of certain growth factors (EGF & TGF-alpha) to bind and signal the cell to promote tumor cell growth, survival and progression. The difference between the two is that Abgenix version is a fully human antibody, whereas, Erbitux is a mouse IgG1 isotop antibody. What this basically means is that ABX-EGF is safer. The downside is that ABX-EGF is still in Phase II, so it'll be a while before it hits the market. This news for Erbitux is, however, very positive for the future of ABX-EGF.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next